Therapeutic agents
US8071585B2 · kind B2 · utility
0Cited by
53References
5Claims
0Family size
Assignee
Inventor
Key dates
| Filing date | Apr 8, 2010 |
| Grant date | Dec 6, 2011 |
| Priority date | — |
| Expiry date | Apr 8, 2030 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P3/10
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A compound (2S)-2-[1-(2,6-dichlorophenyl)pyrazolo[4,5-e]pyrimidin-4-yl]oxy-3-(3-hydroxyazetidin-1-yl)-N-(5-methylpyrazin-2-yl)propanamide is useful in the treatment or prevention of a disease or medical condition mediated through glucokinase (GLK or GK), leading to a decreased glucose threshold for insulin secretion.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.